News | November 15, 2011

PARTNER Trial Follow-Up Supports TAVR Superiority

November 15, 2011 — A two-year study of patients in the landmark PARTNER trial confirms the one-year findings and supports transcatheter aortic valve replacement (TAVR) as the standard-of-care. The original study compared TAVR  in patients who have severe aortic stenosis and are not candidates for open-heart surgery. The results were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.  

Cohort B of the PARTNER trial consisted of those patients with severe aortic stenosis who were not candidates for surgery. 358 patients were randomized to transfemoral TAVR with an early generation balloon-expandable bovine pericardial valve or standard therapy (ST, including balloon valvuloplasty) at 21 centers, emphasizing a multidisciplinary heart team approach.

The primary endpoint was death from any cause at one year; secondary endpoints included symptom status, serial echo assessments (core lab) and early/late adverse events (e.g. strokes).

After two years, the rate of all-cause mortality was 18.2 percent in the TAVR group and 35.1 percent in the standard therapy group. The rate of cardiovascular mortality was 13.2 percent in the TAVR group and 32.1 percent in the standard therapy group.

The rate of repeat hospitalization was 35 percent in the TAVR group and 72.5 percent in the standard therapy group.

The rate of stroke at two years was higher – 13.8 percent in the TAVR group and 5.5 percent in the standard therapy group.

“At two years, in patients with symptomatic severe aortic stenosis who are not suitable candidates for surgery, TAVR remained superior to standard therapy with incremental benefit from one to two years markedly reducing the rates of all cause mortality, cardiovascular mortality and repeat hospitalization,” said Raj R. Makkar, M.D., the principal site investigator for the PARTNER trial. Makkar is director of interventional cardiology and the Cardiac Catheterization Laboratory at Cedars-Sinai Medical Center. He is also associate director of the Cedars- Sinai Heart Institute

“There were more neurologic events in TAVR patients compared to standard therapy (16.2 percent vs. 5.5 percent; p = 0.003) with five new events (three strokes and two TIAs) between one and two years in TAVR patients. After 30 days, differences in stroke frequency were largely due to increased hemorrhagic strokes in TAVR patients.” Makkar said.

“Two year data continues to support the role of TAVR as the standard-of-care for symptomatic patients with aortic stenosis who are not surgical candidates,” he said.

“The ultimate value of TAVR in ‘inoperable’ patients will depend on careful selection of patients who are not surgical candidates, and yet do not have extreme co-morbidities that overwhelm the benefits of TAVR.”

The PARTNER trial was funded by Edwards Lifesciences Inc. Makkar reported consulting fees, grant support and lecture fees from Medtronic, equity from Entourage Medical Technologies and grant support from St. Jude Medical.

For more information: www.crf.org

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init